Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that it has raised $35 million in Series B funding, led by Kurma Partners’ Growth Opportunities Fund, with participation from existing investors Seroba Life Sciences and Irish, U.S. and Canadian based family offices and Enterprise Ireland.
ELMC Rx Solutions, LLC (“ELMCRx”) is pleased to announce its independent launch. This follows its purchase by Principal Owner and CEO, Richard Fleder, from its former parent, ELMC Risk Solutions, LLC (“ELMC”).
7wireVentures, one of the country’s leading digital health venture capital firms, today announced the successful completion of a $217 million Growth & Opportunity “GO” Fund, its largest to date.
Augmedics, a pioneer in augmented reality (AR) surgical navigation, today announced the appointment of Tal Davidson, MD as Vice President, Research & Development.
Commercial partnership enables users of Together’s app to access enhanced mental health tracking through Sonde’s leading voice technologyBOSTON--(BUSINESS WIRE)--Leading enterprise vocal biomarker company Sonde Health has partnered with Together, an A...
Parsley Health, a digital health company designed to lower costs in patients with complex and chronic conditions using root cause medicine, today announced survey findings that reveal the state of health of women in the workforce in 2023, and the impact on employers.
Massive Bio Inc., a trailblazing entity in the realm of digital health technology, proudly announces a pivotal advancement in clinical trial recruitment, fortified by a strategic relationship with Evernorth Health, Inc (ENI).
COMISAIR study is now the longest prospective real-world CGM study ever conducted, demonstrating significant and continued HbA1c reduction for patients using real-time CGM over seven years.1 New data shows the Dexcom ONE CGM system delivers a clinic...
BioAlberta has published its 2023 State of the Industry (SOI) report. This year’s report includes new insights and trends from the industry to reflect market conditions and the growth of the sector. The report’s resu...
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, with $150 million under management, today announced the launch...